Status:

COMPLETED

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

All Genders

20-35 years

Phase:

PHASE1

Brief Summary

Study to investigate the bioequivalence of BIBR 277 tablet (Erythritol based) vs. BIBR 277 capsule

Eligibility Criteria

Inclusion

  • Age \>= 20 and \<= 35 years
  • Weight: BMI \>= 17.6 and \<= 26.4 (Weight (kg) / Height (m)2)
  • Subjects judged by the investigator to be eligible as study subjects, with no clinically significant findings after screening
  • Subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent

Exclusion

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Chronic or relevant acute infections
  • History of hepatic disorder (e.g., biliary cirrhosis, cholestasis)
  • History of serious renal disorder
  • History of or present bilateral renal artery stenosis or lack of unilateral kidney accompanying arterial stenosis
  • History of or present cerebrovascular disorder
  • History of hyperkalemia
  • History of hypersensitivity to active ingredient (Telmisartan) or other angiotensin II receptor antagonists
  • History of or present orthostatic hypotension or faint
  • Surgery of gastrointestinal tract (except appendectomy)
  • History of alcohol or drug abuse
  • Participation to another trial with an investigational drug within 4 months prior to the trial
  • Whole blood donation more than 400 mL within 3 months prior to the trial
  • Whole blood donation more than 100 mL within 1 month prior to the trial
  • Donation of constituent of blood of more than 400 mL within 1 month prior to the trial
  • Any medication which might influence the result of the trial within 10 days prior to the trial
  • Excessive physical activities within 7 days prior to the trial
  • Alcohol drinking within 3 days prior to the trial
  • Inability to comply with restriction of protocol
  • Other than above, those who are judged by the investigator to be inappropriate as the subjects of the study

Key Trial Info

Start Date :

July 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT02262559

Start Date

July 1 2002

Last Update

October 13 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.